Blackstone Life Sciences backs Sanofi clinical trials

Patients with multiple myeloma, a rare cancer affecting white blood cells, may have new treatments available thanks to a €300 million ($330 million) collaboration between Blackstone Life Sciences (BXLS) and Sanofi.

French pharmaceutical company Sanofi will use the capital to accelerate its global pivotal studies and in the clinical development program for Sarclisa, a multiple myeloma treatment that uses a subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa. The pivotal study is slated to begin in the second half of 2022.

If the treatment is successful, BXLS will be eligible to receive royalties . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!